

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) Publication number:

0 084 898
A2

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 83200047.5

(51) Int. Cl. 9: **A 61 K 9/50**

(22) Date of filing: 13.01.83

(30) Priority: 22.01.82 GB 8201883
17.07.82 GB 8220762(71) Applicant: **FISONS plc, Fison House Princes Street,
Ipswich Suffolk IP1 1QH (GB)**(43) Date of publication of application: 03.08.83
Bulletin 83/31(72) Inventor: **Augstein, Joachim, Alderman Haw Farm
Charley Road Woodhouse Eaves, Loughborough
Leicestershire (GB)**
Inventor: **Ahmed, Maqbool, 71 Barsby Drive,
Loughborough Leicestershire (GB)**(84) Designated Contracting States: **AT BE CH DE FR GB IT
LI LU NL SE**(74) Representative: **Craig, Christopher Bradberry et al,
Fisons plc 12 Derby Road, Loughborough Leicestershire
LE11 0BB (GB)**(54) **Liposome and sodium cromoglycate compositions, and methods for their preparation.**

(57) There is described a pharmaceutical composition comprising liposomes and sodium cromoglycate.

There is also described an aqueous suspension comprising sodium cromoglycate partitioned between a free aqueous phase and a liposome phase.

There is further described a method for making the compositions, and their use in the treatment of allergic conditions, e.g., asthma.

EP 0 084 898 A2

LIPOSOME AND SODIUM CROMOGLYCAT E COMPOSITIONS, AND METHODS FORTHEIR PREPARATION

This invention relates to pharmaceutical compositions and more particularly it relates to the formulation of substances for inhalation.

5 Sodium cromoglycate has been known for a number of years for the treatment of allergic conditions, for example asthma, hay fever and vernal kerato conjunctivitis; however it suffers from the disadvantage that it is of relatively short duration of action.

10 According to the invention there is provided a pharmaceutical composition comprising liposomes and sodium cromoglycate.

By administering the liposomes of this invention directly into the site of the allergic condition, e.g. the
15 lung, it is possible to effect an increased level of retention of sodium cromoglycate at the site, thereby obtaining increased duration of action.

The initial stages of the preparation of liposomes according to the present invention may conveniently follow
20 procedures described in the art, i.e. the lipid starting materials being dissolved in a solvent, e.g. ethanol or chloroform, which is then evaporated. The resulting lipid layer is then dispersed in the selected aqueous medium containing an appropriate concentration of sodium
25 cromoglycate. In contradistinction to the usual practice,

however, it is preferred not to sonicate the liposomes thus produced, since this reduces their size. The liposomes produced by our procedure will usually be of a range of sizes. The liposomes of this invention
5 preferably have a diameter of between 100nm. and 10 μ m, more preferably they have a diameter of between 1 μ m and 7 μ m. It is known, for example, that liposomes having a diameter of up to 5000nm. may be readily phagocytosed. It is preferred that the liposomes are fractionated to remove
10 substantially all those having a diameter less than 100nm., and preferably also those having a diameter less than 1 μ m. Fractionation may conveniently be effected by column gel chromatography, for example using cross linked dextran or agarose, the size of the gel being selected
15 according to the desired liposome size. Alternatively, the liposomes may be fractionated using ultracentrifugation, or by dialysis, e.g. using polycarbonate membrane filtration.

A wide variety of lipid materials may be used to form
20 the liposomes including natural lecithins, e.g. those derived from egg and soya bean, and synthetic lecithins. Lipids which are non-immunogenic and bio-degradable are preferred. The properties of the lipid, for example its phase transition temperature, can have a marked effect on
25 the retention and uptake of the liposomes in the target

organ and for this reason the well defined synthetic lecithins are preferred to the natural lecithins.

Examples of synthetic lecithins which may be used, together with their respective phase transition

5 temperatures, are di-(tetradecanoyl)phosphatidylcholine

(DTPC) (23°C), di-(hexadecanoyl)phosphatidylcholine

(DHPC) (41°C) and di-(octadecanoyl)phosphatidylcholine

(DOPC) (55°C). We prefer to use di-(hexadecanoyl)

phosphatidylcholine as the sole or major lecithin,

10 optionally together with a minor proportion of the di-(octadecanoyl) or the di-(tetradecanoyl) compound.

Other synthetic lecithins which may be used are

unsaturated synthetic lecithins, for example

di-(oleyl)phosphatidylcholine and di-(linoleyl)-

15 phosphatidylcholine. We prefer the synthetic lecithin, or

the mixture of lipids, to have a phase transition

temperature in the range $35-45^{\circ}\text{C}$. In addition to the

main liposome-forming lipid or lipids, which are usually

phospholipids, other lipids (e.g. in a proportion of 5 -

20 40% w/w of the total lipids) may be included, for example

cholesterol or cholesterol stearate, to modify the

structure of the liposome membrane, rendering it more

fluid or more rigid depending on the nature of the main

liposome-forming lipid or lipids. An optional third

25 component is a material which provides a negative charge,

for example phosphatidic acid, dicetyl phosphate or beef
brain ganglioside, or one which provides a positive charge
for example stearylamine acetate or cetylpyridinium
chloride. The charged component may be included in a
5 proportion of 1-20% w/w of the total lipids.

A wide range of proportions of sodium cromoglycate to
lipid during formation may be used depending on the lipid
and the conditions used. However we have in general found
that a range of one part by weight of sodium cromoglycate
10 to from 0.01 to 100, preferably 0.05 to 20, most
preferably 0.1 to 10 parts by weight of lipid is
appropriate. We prefer to use as high a proportion of
sodium cromoglycate as is practicable.

The concentration of sodium cromoglycate in the
15 aqueous phase during liposome formation is preferably in
the range 0.01 to 50mg/ml, and more preferably 0.1 to
20mg/ml, e.g. 10 or 20mg/ml.

We prefer the aqueous phase to contain less than 20
ppm of metal ions in group IIa, Ib, IIb and IVb of the
20 periodic table, and of the transition metals, in
particular Pb^{++} , Ca^{++} , Mg^{++} , Fe^{++} , Fe^{+++} and
 Zn^{++} ions.

The aqueous phase may be made isotonic, using sodium
chloride. In addition the aqueous phase may contain
25 potassium chloride.

The aqueous phase may be adjusted to a pH of between 6 and 8, and preferably 6.5 to 7.5 by the addition of acid or base as appropriate, or by the addition of a suitable buffering agent, e.g. tris(hydroxymethyl)methanamine (Tris).

The concentration of lipid dispersed in the aqueous phase is preferably in the range 0.1 to 150mg/ml, more preferably 0.5 to 50mg/ml and most preferably 1 to 30mg/ml.

We prefer the liposome formulation to have a half life (efflux rate) at 37°C of from about 12 to 48 and preferably 12 to 24 hours. Half lives may be measured using conventional techniques, e.g. by dilution methods. The half life of the formulation may be varied by varying the proportion of the various lipids used to make the liposome.

The compositions of the invention may be used for the treatment of asthma, by instilling a nebulised aqueous suspension of the sodium cromoglycate liposomes into the lungs. The compositions of the invention may be used as eye drops in the treatment of allergic eye conditions, e.g. vernal kerato conjunctivitis, the ocular symptoms of hay fever and/or marginal infiltration.

The compositions may also be used in the treatment of diseases of gastro-intestinal tract, e.g. ulcerative colitis, and food allergies, by oesophageal

administration. Enemas incorporating the compositions may be used in the treatment of bowel diseases, particularly of allergic origin. The compositions may also be used in the treatment of hay fever, by administration to the nose, 5 e.g. as a nasal spray, and in the treatment of skin conditions, e.g. chronic dermatoses in mammals, notably man. Dermatoses which may be treated include those involving skin mast cells and/or antibody antigen reactions and include eczemas, drug eruptions, psoriasis, 10 dermatitis, herpetiformis pemphigus and chronic skin ulcers.

The compositions produced as described above are aqueous suspensions of liposomes in which sodium cromoglycate is partitioned between the free aqueous phase 15 and the liposome phase.

We find that these aqueous formulations have useful and unexpected properties, in that the aqueous phase can provide an initial 'priming' dose of sodium cromoglycate, and the liposome phase can provide a maintenance dose of 20 sodium cromoglycate. This has the effect of increasing the duration of action of sodium cromoglycate.

According to the invention, we therefore provide an aqueous suspension comprising sodium cromoglycate partitioned between a free aqueous phase and a liposome 25 phase.

We prefer the total concentration of sodium cromoglycate in the aqueous suspension to be from 0.01 to 50mg/ml, and preferably 0.1 to 20mg/ml.

We prefer the percentage of sodium cromoglycate associated with the liposomes to be from 2 to 35% w/w, e.g. from 4 to 20%. The percentage of sodium cromoglycate associated with the liposomes can be determined by conventional methods, e.g. centrifugation.

Alternatively, the aqueous suspension of sodium cromoglycate partitioned between an aqueous phase and a liposome phase, may be concentrated, e.g. by centrifugation, ultrafiltration or dialysis, to give a liposome gel. This gel may be used in several ways, e.g. it may be incorporated in an ointment base, resuspended in water or an isotonic, buffered saline solution, which may optionally contain sodium cromoglycate. Such formulations may be made up from the liposome gel, and suitable excipients immediately prior to use.

The dosage given will vary with the particular compositions used, the condition to be treated and its severity. We prefer to use an effective amount of sodium cromoglycate liposomes (e.g. for inhalation treatment of asthma, from 0.1 to 20mg) in the treatment of these conditions.

The invention is illustrated, but in no way limited

by the following Examples.

General procedure for preparing sodium cromoglycate
containing liposomes

The desired quantity (e.g. 20mg) of the appropriate
5 phospholipid or mixture of phospholipids (e.g. egg
lecithin, DTPC, DHPC or DOPC), together if desired with
any other lipid soluble components (e.g. cholesterol,
cholesterol stearate) is weighed into a round bottom
flask. The lipid component is dissolved in a small
10 quantity (ca 5ml) of a suitable solvent (e.g. ethanol),
and evaporated to dryness under reduced pressure using a
rotary film evaporator, to leave a thin film of
phospholipid on the inner surface of the flask.

An aqueous solution of sodium cromoglycate of
15 appropriate concentration (e.g. 1mg/ml) is prepared by
dissolving a weighed amount of sodium cromoglycate in 20ml
of an aqueous medium (e.g. 0.9% w/v saline solution,
buffer solution, etc) and if desired the pH of the
resulting solution. The aqueous solution of the sodium
20 cromoglycate is warmed to a temperature 20°C above the
phase transition temperature of the lipid(s), added to the
lipid film in the flask, and the flask gently shaken until
all the lipid film is dispersed. The resulting suspension
contains liposomes ranging from 200nm to 10um in size.

25 The suspension was allowed to equilibrate for 48

hours, at 37°C.

These suspensions contain sodium cromoglycate partitioning between the free aqueous phase and the liposome phase.

5 After 24 hours the suspension in most cases separates out to form a colloidal white precipitate, which is readily redispersed on shaking.

The following sodium cromoglycate liposomes compositions were prepared using the above general
10 procedure:

	1.	Egg lecithin	20mg
		Sodium cromoglycate	200mg
		Demineralised water	20ml
15	2.	Egg lecithin	20mg
		Sodium cromoglycate	20mg
		Demineralised water	20ml
20	3.	DTPC	20mg
		Sodium cromoglycate	2mg
		0.9% w/v saline solution	20ml
25	4.	DTPC	20mg
		Sodium cromoglycate	20mg
		0.9% w/v saline solution	20ml

5	5.	DTPC	20mg
		Sodium cromoglycate	200mg
		0.9% w/v saline solution	20ml
5	6.	DTPC	200mg
		Sodium cromoglycate	200mg
		0.9% w/v saline solution	20ml
10	7.	DTPC	400mg
		Sodium cromoglycate	200mg
		0.9% w/v saline solution	20ml
15	8.	DHPC	200mg
		Sodium cromoglycate	200mg
		0.9% w/v saline solution	20ml
20	9.	DOPC	200mg
		Sodium cromoglycate	200mg
		Demineralised water	20ml
25	10.	DTPC	133mg
		Cholesteryl stearate	67mg
		Sodium cromoglycate	200mg
		Demineralised water	20ml

5	11.	DHPC	133mg
		Cholesterol stearate	67mg
		Sodium cromoglycate	200mg
		Demineralised water	20ml
10	12.	DHPC	133mg
		Cholesterol	67mg
		Sodium cromoglycate	200mg
		Demineralised water	20ml
15	13.	DHPC	20mg
		Sodium cromoglycate	200mg
		0.9% w/v saline solution	20ml
	14.	DHPC	75mg
20		Sodium cromoglycate	102.5mg
		150mM potassium chloride	10ml
		10mM Tris buffer, pH7.4	
		in water	
25	15.	DHPC	70mg
		DTPC	30mg
		Sodium cromoglycate	100mg
		0.9 w/v saline solution	10ml

16.	DHPC	180mg
	Sodium cromoglycate	200mg
	Cetylpyridinium chloride	20mg
	0.9 w/v saline solution	200ml

5 Determination of percentage sodium cromoglycate associated with liposomes

The equilibrated, sodium cromoglycate liposome dispersion is centrifuged at 70,000G for one hour. Aliquots of the supernatant are assayed in an ultraviolet
10 spectrophotometer, at 326nm, to determine concentration of free sodium cromoglycate.

The percentage of sodium cromoglycate associated with the liposomes is determined from the relationship:
percentage sodium cromoglycate (cromoglycate) associated
15 with liposome =

$$\frac{[\text{Total cromoglycate}] - [\text{cromoglycate in supernatant}] \times 100}{[\text{Total cromoglycate}]}$$

The following percentage associations were determined:

	Example	5	4.5% w/w
20		13	8.23% w/w
		14	14.00% w/w

Rate of sodium cromoglycate release from liposomes, and liposome half-life

The rate of sodium cromoglycate release from the
25 liposomes may be determined by centrifuging the sodium

cromoglycate liposomes at 70,000G as above, discarding the supernatant and resuspending in isotonic saline, buffered at pH7.4. Aliquots of the resuspended liposomes, agitated at 37°C, were centrifuged at intervals, and the concentration of sodium cromoglycate in the supernatant determined by u.v. spectrophotometry. The release constant, k , of the liposome is determined by plotting \ln [cromoglycate released] v time

The half-life of the liposome, $t_{\frac{1}{2}}$, is given by the relationship $t_{\frac{1}{2}} = \frac{\ln 2}{k}$

Liposome half lives may also be determined using the dilution method described by M Ahmed et al, Biochemical Pharmacology, 29, 2361-2365, (1980).

Determination of flux and permeability coefficient

Preparation of Membranes

Albino hairless mice of either sex and aged 10 to 12 weeks were sacrificed by cervical dislocation and the dorsal skin removed with the minimum of handling. Any subcutaneous fat, visible as discrete globules, was removed. The skin samples were examined for any signs of damage before use. One skin sample was used per diffusion cell and was mounted, epidermal side up, over the opening in the upper section of the diffusion cell and was then secured with an 'O' ring. Excess skin was trimmed away.

before assembly of the cell.

Diffusion Cell Assembly

5 A small amount of silicone grease was applied to the
'O' ring of the upper section after securing the
membrane. The upper section was then pushed firmly into
the lower chamber until correctly positioned. The chamber
was then filled with saline pre-equilibrated to 37°. The
volume of each cell was adjusted individually to
10 ensure that the skin membrane remained level. The fill
volume was then marked on the sidearm.

Experimental Procedure

15 The set of eight diffusion cells were mounted on a
carrier plate held in a thermostatically controlled water
bath set at 37° and were allowed to equilibrate. Each
cell was positioned over an underwater magnetic stirrer
motor and the water level was adjusted to be approximately
the same as the skin surfaces. This ensured that the
temperature of the skin surface remained at 30°.

20 The vehicle to be studied was applied, either by
delivery from a micropipette. The preparation was then
evenly distributed over the exposed skin surface using a
small glass rod. The weight of each aliquot applied was
determined by accurately weighing at least 10 samples
25 delivered by the micropipette or syringe.

Following application of the vehicle the magnetic

stirrers were switched on and at appropriate time intervals 1.0ml samples of the receptor fluid were removed via the side arms and immediately replaced with fresh saline pre-equilibrated to 37⁰. The samples were then
5 deep frozen until analysed for the drug by High Performance Liquid Chromatography (HPLC).

At least three replicate diffusion cells were used for each formulation studied.

Data Handling

10 Assuming that only passive diffusion occurs during the transport of the drug across the skin, the rate of penetration can be given by Fick's law.

$$J = P \Delta C$$

Where J is the flux, the amount of drug diffusing per unit
15 area per unit time,
P is the permeability coefficient
 ΔC is the concentration difference across the stratum corneum.

20

25 7888Fir/gel

What we claim is:

1. A pharmaceutical composition comprising liposomes and sodium cromoglycate.
2. An aqueous suspension comprising sodium cromoglycate partitioned between a free aqueous phase and a liposome phase.
3. A composition according to Claim 1 or 2, wherein the liposomes have a diameter between 100nm and 10 μ m.
4. A composition according to any one of the preceeding Claims wherein the liposomes comprise one or more natural or synthetic lecithins.
5. A composition according to Claim 4, wherein the lecithin, or mixture of lecithins, has a phase transition temperature in the range 35-45°C.
6. A composition according to Claim 4 or Claim 5 wherein the liposomes contain one or more additional components selected from cholesterol, cholesterol stearate and a negatively or positively charged component.
7. A composition according to any one of the preceeding Claims, wherein the ratio by weight of sodium cromoglycate to lipid is from 0.01 to 100.
8. An aqueous suspension according to any one of Claims 2 to 7, wherein the total concentration of sodium cromoglycate is from 0.01 to 50mg/ml.

9. A composition according to any one of the preceeding Claims, wherein the percentage of sodium cromoglycate associated with the liposomes is from 2 to 35% w/w.
10. A method of making a pharmaceutical composition according to Claim 1 or Claim 2, which comprises dispersing a thin film of lipid in an aqueous solution of sodium cromoglycate.
11. An aqueous suspension comprising a total concentration of from 0.1 to 20mg/ml sodium cromoglycate partitioned between an aqueous phase and a liposome phase, the liposome phase comprising one or more of the lecithins di-(tetradecanoyl)phosphatidylcholine, di-(hexadecanoyl)phosphatidylcholine or di-(octadecanoyl)phosphatidylcholine, wherein the concentration of the lecithins dispersed in the aqueous phase is from 1 to 30mg/ml and the percentage of sodium cromoglycate associated with the liposomes is from 2 to 35% w/w.

• What we claim is:

1. A method of making a pharmaceutical composition comprising liposomes and sodium cromoglycate which comprises dispersing a thin film of lipid in an aqueous solution of sodium cromoglycate.
5
2. A method of making an aqueous suspension comprising sodium cromoglycate partitioned between a free aqueous phase and a liposome phase which comprises dispersing a thin film of lipid in an aqueous solution of sodium cromoglycate.
10
3. A method according to Claim 1 or 2, wherein the liposomes have a diameter between 100nm and 10µm.
4. A method according to any one of the preceeding Claims wherein the liposomes comprise one or more natural or synthetic lecithins.
15
5. A method according to Claim 4, wherein the lecithin, or mixture of lecithins, has a phase transition temperature in the range 35-45°C.
6. A method according to Claim 4 or Claim 5 wherein the liposomes contain one or more additional components selected from cholesterol, cholesterol stearate and a negatively or positively charged component.
20
7. A method according to any one of the preceeding Claims, wherein the ratio by weight of sodium cromoglycate to lipid is from 0.01 to 100.
25

8. A method according to any one of the preceding Claims, wherein the total concentration of sodium cromoglycate is from 0.01 to 50mg/ml.
- 5 9. A method according to any one of the preceding Claims, wherein the percentage of sodium cromoglycate associated with the liposomes is from 2 to 35% w/w.
- 10 10. A method according to Claim 2, wherein a total concentration of from 0.1 to 20mg/ml sodium cromoglycate is partitioned between an aqueous phase and a liposome phase, the liposome phase comprising one or more of the lecithins di-(tetradecanoyl)phosphatidylcholine, di-(hexadecanoyl)phosphatidylcholine or di-(octadecanoyl)phosphatidylcholine, the concentration of the lecithins, dispersed in the aqueous phase is from 1 to 30mg/ml and the percentage of sodium cromoglycate associated with the liposomes is from 2 to 35% w/w.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.